Chest
Special FeaturesLong-term Course and Prognosis of Idiopathic Pulmonary Fibrosis in the New Millennium
Section snippets
Materials and Methods
We performed a review of all patients with IPF who were seen at the Inova Fairfax Hospital Interstitial Lung Disease Clinic between January 2000 and November 2009. The clinic maintains a database of all patients evaluated, with data entered prospectively at the time of their initial evaluation. This database was used as the source in identifying the cohort. When available, chart reviews were performed for missing data to provide as complete a data set as possible. Patients were given a
Baseline Data and Demographics
There were 521 patients with IPF who were seen and evaluated in the clinic during the 10-year period. The demographics of the cohort and PFT data at the time of initial evaluation, which were available in 446 of the patients, are shown in Table 1. The date of the PFT was in many cases different from the date of the patient's initial evaluation. Most of the PFTs (273 of 446, 61.2%) were within 90 days of the initial evaluation, with a median time difference of 45.7 days. In most cases (337 of
Discussion
IPF is a disease with a poor prognosis that appears unchanged over the past decade in comparison with the pre-ATS/ERS statement period. The median survival in our nontransplantation IPF cohort of about 3.5 years is very similar to survival rates reported prior to the publication of the statement.2, 3, 4 Of patients who were considered for enrollment in a prospective therapeutic study, only 27% qualified despite the availability and contiguity of multiple clinical trials, whereas only 16% of the
Acknowledgments
Financial/nonfinancial disclosure: The authors have reported to CHEST the following conflicts of interest: Dr Nathan has served as a consultant for InterMune, Gilead, Bayer, United Therapeutics, and Actelion. He also has received research funding from InterMune, Gilead, Bayer, United Therapeutics, and Actelion. Dr du Bois has served as a consultant, study steering committee member, or chairman of a steering committee for Actelion, Boehringer-Ingelheim, Bayer, Genzyme, InterMune, and
References (27)
- et al.
Recent advances in idiopathic pulmonary fibrosis
Chest
(2007) - et al.
Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial
Lancet
(2009) - et al.
International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation
J Heart Lung Transplant
(2006) - et al.
The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report–2010
J Heart Lung Transplant
(2010) - et al.
Disease-specific survival benefit of lung transplantation in adults: a national cohort study
Am J Transplant
(2009) - et al.
Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis
J Thorac Cardiovasc Surg
(2003) - et al.
Listing for lung transplantation: life expectancy and transplant effect, stratified by type of end-stage lung disease, the Eurotransplant experience
J Heart Lung Transplant
(2001) - et al.
Assessment of survival benefit after lung transplantation by patient diagnosis
J Heart Lung Transplant
(2002) - et al.
Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment
Am J Med
(1990) - et al.
Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model
Am J Respir Crit Care Med
(2001)
Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis
Am J Respir Crit Care Med
A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis
Am J Respir Crit Care Med
Idiopathic pulmonary fibrosis: predicting response to therapy and survival
Am J Respir Crit Care Med
Cited by (276)
Emerging role of immune cells as drivers of pulmonary fibrosis
2023, Pharmacology and TherapeuticsAssociation Between Interstitial Lung Disease and Outcomes After Lung Cancer Resection
2023, Annals of Thoracic SurgeryIdiopathic pulmonary fibrosis: Diagnosis, biomarkers and newer treatment protocols
2023, Disease-a-Month
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).